<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02226367</url>
  </required_header>
  <id_info>
    <org_study_id>W81XWH-12-2-0094</org_study_id>
    <nct_id>NCT02226367</nct_id>
  </id_info>
  <brief_title>Prazosin Augmentation of Outpatient Treatment of Alcohol Use Disorders in Active Duty Soldiers With and Without PTSD</brief_title>
  <official_title>Prazosin Augmentation of Outpatient Treatment of Alcohol Use Disorders in Active Duty Soldiers With and Without PTSD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seattle Institute for Biomedical and Clinical Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>United States Department of Defense</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>VA Puget Sound Health Care System</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Seattle Institute for Biomedical and Clinical Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate if the drug prazosin:&#xD;
&#xD;
        -  will decrease alcohol use in active duty members of the military who served in Iraq&#xD;
           and/or Afghanistan and&#xD;
&#xD;
        -  determine if presence or absence of posttraumatic stress disorder affects treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The proposed study is a 19-week, titration to stable dose, randomized, two-group&#xD;
      parallel-design, double-blind, placebo-controlled trial to evaluate the efficacy of prazosin&#xD;
      for decreasing alcohol use in 200 active duty Service Members who served in the conflicts in&#xD;
      Iraq and/or Afghanistan who are receiving standard outpatient treatment for alcohol use&#xD;
      disorders at Joint Base Lewis-McChord. Treatment groups will be stratified by presence or&#xD;
      absence of posttraumatic stress disorder (PTSD) and by assignment to the 6-week or 12-week&#xD;
      Army Substance Abuse Program. The hypotheses are that: 1) prazosin is more effective than&#xD;
      placebo for alcohol use disorders in these Service Members; and 2) that prazosin effect size&#xD;
      will be greater in Service Members with PTSD than without PTSD.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Actual">October 20, 2018</completion_date>
  <primary_completion_date type="Actual">September 20, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Penn Alcohol Craving Scale score</measure>
    <time_frame>Change at Week 13 from Baseline</time_frame>
    <description>A self-report paper-and-pencil instrument that assesses various dimensions of craving for alcohol and has been found to have good reliability and validity.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">211</enrollment>
  <condition>Alcohol Use Disorders</condition>
  <condition>Stress Disorders, Posttraumatic</condition>
  <condition>Combat Disorders</condition>
  <arm_group>
    <arm_group_label>prazosin hydrochloride</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Prazosin hydrochloride taken orally. Titrated to a maximum dose 4 mg in the morning, 6 mg in the afternoon, and 10 mg at bedtime. (20 mg total daily at maximum dose) Dose increase will occur if the participant does not have unacceptable side effects.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo. Oral capsule with comparable appearance to active treatment. Titrated in same manner as active treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prazosin hydrochloride</intervention_name>
    <description>study drug arm prazosin</description>
    <arm_group_label>prazosin hydrochloride</arm_group_label>
    <other_name>prazosin</other_name>
    <other_name>Pfizer Minipress</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>study drug arm placebo</description>
    <arm_group_label>placebo</arm_group_label>
    <other_name>sugar pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Male and female active duty returnees from the conflicts in Iraq and/or Afghanistan&#xD;
             over the age of 21 with a current Diagnostic and Statistical Manual of Mental&#xD;
             Disorders IV diagnosis of Alcohol Abuse or Dependence or a current Diagnostic and&#xD;
             Statistical Manual of Mental Disorders 5 diagnosis of Alcohol Use Disorder&#xD;
&#xD;
          -  Participant in Army Substance Abuse Program (6 or 12 week program)&#xD;
&#xD;
          -  Recent alcohol consumption: more than 14 (women) or 21 (men) drinks per week for at&#xD;
             least 2 weeks in the past 60 day period OR at least 2 days of heavy drinking in the&#xD;
             past 60 day period (4 or more drinks for women and 5 or more drinks for men)&#xD;
&#xD;
          -  Good general medical health (see Exclusion Criteria below)&#xD;
&#xD;
          -  Women of childbearing potential must agree to abstain from sexual relations that could&#xD;
             result in pregnancy or use an effective method of birth control acceptable to both&#xD;
             participant and the study clinician during the study. Men are not required to use&#xD;
             contraception during the study.&#xD;
&#xD;
          -  Concomitant use of naltrexone and/or antabuse must be stable for 2 weeks prior to&#xD;
             Baseline&#xD;
&#xD;
          -  Capacity to provide informed consent&#xD;
&#xD;
          -  English fluency&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Current diagnosis of opioid, methamphetamine, cocaine, marijuana, or other illegal&#xD;
             substance dependence or abuse.&#xD;
&#xD;
          -  Signs or symptoms of alcohol withdrawal at the time of initial consent&#xD;
&#xD;
          -  Current diagnosis of schizophrenia, other psychotic disorder, manic phase of bipolar&#xD;
             disorder, or cognitive disorder.&#xD;
&#xD;
          -  Suicide attempt or suicidal ideation with intent in the past month.&#xD;
&#xD;
          -  Significant acute or chronic medical illness, including unstable angina, recent&#xD;
             myocardial infarction, history of congestive heart failure, preexisting hypotension&#xD;
             (systolic &lt;100) or orthostatic hypotension (defined as a systolic drop &gt; 20 mmHg after&#xD;
             two minutes standing accompanied by lightheadedness or syncope); insulin-dependent&#xD;
             diabetes mellitus; chronic renal or hepatic failure, acute pancreatitis, Meniere's&#xD;
             disease. Liver function tests more than 5 times the upper limit.&#xD;
&#xD;
          -  Concomitant use of trazodone (due to increased risk of priapism). There will be a two&#xD;
             week trazodone washout period before the baseline visit.&#xD;
&#xD;
          -  Concomitant use of an alpha-1 blocker medication or insulin&#xD;
&#xD;
          -  Use of prazosin in the 4 weeks prior to Baseline.&#xD;
&#xD;
          -  History of prazosin sensitivity/allergy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Murray Raskind, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Veterans Affairs Puget Sound Health Care System</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Madigan Army Medical Center</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98431</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>July 15, 2014</study_first_submitted>
  <study_first_submitted_qc>August 25, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 27, 2014</study_first_posted>
  <last_update_submitted>August 28, 2020</last_update_submitted>
  <last_update_submitted_qc>August 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>prazosin</keyword>
  <keyword>alcohol use disorders</keyword>
  <keyword>posttraumatic stress disorder</keyword>
  <keyword>PTSD</keyword>
  <keyword>combat trauma</keyword>
  <keyword>military</keyword>
  <keyword>alpha-1 adrenoreceptor antagonist</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Alcoholism</mesh_term>
    <mesh_term>Stress Disorders, Traumatic</mesh_term>
    <mesh_term>Alcohol Drinking</mesh_term>
    <mesh_term>Combat Disorders</mesh_term>
    <mesh_term>Stress Disorders, Post-Traumatic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prazosin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

